Investors
Investera i framtidens hälsoteknik – delta i Attanas emission
Attana banar väg för individanpassade immunitetstest med en unik teknologi som simulerar kroppens miljö. Delta i emissionen och bli en del av vår resa.
Events & presentations
Redeye Medtech 2025
At the event, CEO Anna Hellergård presented Attana’s unique QCM technology, emphasizing real-time measurement of molecular interactions without labeling. She outlined the company’s two business areas, recent progress, and focus on scalable growth, commercialization, and the upcoming TO2 in May/June 2025.
Aktiespararna Life Science Day 2025
Presentation by CEO Anna Hellergård (2025-04-23)
At the event, CEO Anna Hellergård highlighted Attana’s unique QCM technology and its ability to measure molecular interactions in real-time within complex biological environments—without labeling or purification.The presentation covered Attana’s two business areas, recent scientific and commercial progress, and the company’s focus on scalable growth, increased commercialization, and upcoming TO2 in May/June 2025.
Småbolagsdagarna 2022
Our presentation at Aktiespararna’s “Småbolagsdagarna” (2022-06-14)
CEO Teodor presented our two business areas, Attana Life Science and Attana Diagnostics and focus on both the short- and long-term plans going forward.
Erik Penser Bank Bolagsdag 2022
CEO Teodor Aastrup’s presentation at Erik Penser Bank’s Bolagsdag (2022-03-10).
An introduction to Attana, our track record within Life Science and an update on our patent portfolio.
Biotech Showcase 2022
Our presentation at Biotech Showcase 2022.
CEO Teodor presents Attana’s business units – Life Science and Diagnostics.
Stora Aktiedagen 2021 (Pitch)
Our elevator pitch at Aktiespararna’s “Stora Aktiedagen” (2021-12-01)
CEO Teodor gives an elevator pitch on Attana and our business.
Investera i framtidens hälsoteknik – delta i nyemissionen
Attana banar väg för individanpassade immunitetstest med en unik teknologi som simulerar kroppens miljö. Delta i nyemissionen och bli en del av vår resa.
Financial information
Financial reports & calendar
External financial reports
2025-02-28 – Bokslutskommuniké 2024
2025-04-22 – Årsredovisning 2024
2025-05-20 – Delårsrapport Q1 2025
2025-05-20 – Signerad årsredovisning med revisionsberättelse
2025-08-22 – Halvårsrapport H1 2025 (januari-juni)
2024-02-23 – Bokslutskommuniké 2024
2024-04-19 – Årsredovisning 2023
2024-05-02 – Årsredovisning 2023 – Revisionsberättelse
2024-05-03 – Delårsrapport Q1 2024 (januari-mars)
2023-02-24 – Bokslutskommuniké 2022
2023-05-04 – Årsredovisning 2022
2023-05-04 – Årsredovisning 2022 – Revisionsberättelse
2023-05-05 – Delårsrapport Q1 2023 (jan-mar)
2022-02-25 – Bokslutskommuniké 2021
2022-04-08 – Årsredovisning 2021
2022-04-08 – Årsredovisning 2021 – Revisionsberättelse
2022-05-06 – Delårsrapport Q1 2022 (jan-mar)
2022-08-19 – Halvårsrapport H1 2022 (jan-jun)
Memorandums & offerings
2022-12-08 – Så här gör du för att teckna aktier i Attana
2018-03-07 – Första handelsdag på NGM
Stock information
Investor relations
Anna Hellergård – CEO
Phone: +46 70 886 23 06
Email: ir@attana.com
News & press
Attana’s press announcements and news are published via Cision. Attana communicates in Swedish or English. Attana AB is required under the Swedish Securities Market Act to disclose certain information and such information is primarily provided in Swedish on the Swedish news room.
Information related to scientific publications from the company’s customers is primarily provided in English on the English news room.
If you wish to receive all information from Attana we recommend that you subscribe for news written in Swedish and English by visiting the news rooms.
Corporate governance
General meetings
2024-10-31 – Kallelse till extra bolagstämma
› Fullmaktsformulär
› Bilaga 1 – Styrelsens redogörelse
› Bilaga 2 – Revisorns yttrande
› Bilaga 3 – Beslut om företrädesemission
› Bilaga 3A – Fullständiga villkor för teckningsoptioner av serie TO 2
› Bilaga 3B – Fullständiga villkor för teckningsoptioner av serie TO 3
› Föreslagen ny bolagsordning
2022-11-23 – Styrelsens redogörelse över väsentliga händelser
2022-11-23 – Revisorns yttrande över styrelsens redogörelse
2022-11-09 – Kallelse till bolagstämma
2022-11-09 – Fullmakt (bolagsstämma)
2020-10-26 – Styrelsens redogörelse över väsentliga händelser (9 november)
2020-10-26 – Revisorns yttrande över styrelsens redogörelse (9 november)
2020-10-26 – Fullständiga förslag till emissionen (9 november)
2020-10-21 – Kallelse till extra bolagsstämma (9 november)
2020-10-21 – Notice to attend extraordinary general meeting (November 9)
2020-05-08 – Årsstämma verksamhetsår 2019
Other company documents
Board of Directors
Arne Nabseth (b. 1963)
Chairman since 2015
25 years of experience in the IT industry. Entrepreneurial experience from building PCM Nordic/MAS, Applicon and Qrodo. Previously venture capitalist at Ledstiernan, IT manager at Philips Electronics, KPMG, Bearing Point Silicon Valley and an angel investor.
Teodor Aastrup (b. 1970)
CSO, Co-Founder & Director since 2013
PhD from KTH Royal Institute of Technology and MSc in Material Physics from Uppsala University. Long experience from defining, developing and commercializing business strategies. Previously responsible for chemical analytics at Scania.
Lena Jendeberg (b. 1964)
Director since 2018
PhD from KTH Royal Institute of Technology with 25+ years of experience in the pharmaceutical industry working at Pharmacia, Biovitrum, Sobi, Modus Therapeutics and Wilson Therapeutics. Have developed pharmaceuticals all the way from the pre-clinical phase to improvement of approved products.
Rolf Lundh
M.D, PhD Karolinska Institute Stockholm
More than 30 years experience from Senior managerial global positions in pharmaceutical research (10 years with Astra and 13 years with the Pharmacia Corporation.